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Abstract
Importance: Skin cancer, in particular squamous cell carci-
noma, is the most frequent malignancy among solid organ 
transplant recipients with a higher incidence compared to 
the general population. Objective: To determine the skin 
cancer incidence in organ transplant recipients in Switzer-
land and to assess the impact of immunosuppressants and 
other risk factors. Design: Prospective cohort study of solid 
organ transplant recipients in Switzerland enrolled in the 
Swiss Transplant Cohort Study from 2008 to 2013. Partici-
pants: 2,192 solid organ transplant recipients. Materials and 
Methods: Occurrence of first and subsequent squamous cell 
carcinoma, basal cell carcinoma, melanoma and other skin 
cancers after transplantation extracted from the Swiss Trans-
plant Cohort Study database and validated by medical re-
cord review. Incidence rates were calculated for skin cancer 
overall and subgroups. The effect of risk factors on the occur-
rence of first skin cancer and recurrent skin cancer was cal-
culated by the Cox proportional hazard model. Results: In 
2,192 organ transplant recipients, 136 (6.2%) developed 335 
cases of skin cancer during a median follow-up of 32.4 
months, with squamous cell carcinoma as the most frequent 
one. 79.4% of skin cancer patients were male. Risk factors for 
first and recurrent skin cancer were age at transplantation, 
male sex, skin cancer before transplantation and previous 
transplantation. For a first skin cancer, the number of immu-
nosuppressive drugs was a risk factor as well. Conclusions 
and Relevance: Skin cancer following solid organ transplan-
tation in Switzerland is greatly increased with risk factors: 
age at transplantation, male sex, skin cancer before trans-
plantation, previous transplantation and number of immu-
nosuppressive drugs.  © 2020 The Author(s)
Published by S. Karger AG, Basel
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Skin cancer represents over one third of all cancer cas-
es in Switzerland [1]. Basal cell carcinoma (BCC) is the 
most common cancer overall in Switzerland and most 
other countries [2, 3]. Squamous cell carcinoma (SCC) is 
the second-most frequent keratinocyte cancer following 
BCC [4]. Most keratinocyte carcinoma in the general 
population is indolent with a low mortality rate but causes 
relevant morbidity [2, 4]. In the setting of immunosup-
pression such as in organ transplant recipients (OTR), the 
incidence of keratinocyte cancers, in particular SCC, in-
creases 65- to 250-fold compared to the general popula-
tion, greatly impacting morbidity and mortality [2, 4–11]. 
Due to improvements in clinical management, ad-
vances in transplantation medicine and immunosup-
pressive medication, outcomes and survival after solid 
organ transplantation have improved over the last few 
years. This, however, leads to an increased incidence of 
cancers after solid organ transplantation [12, 13]. The 
Swiss Transplant Cohort Study (STCS) is a prospective 
cohort study screening all candidates for solid organ 
transplantation since 2008 and finally enrolling them at 
transplantation [14]. The enrolment rate exceeds 95% 
and thus reflects well the transplant recipient population 
in Switzerland [15]. Skin cancers are prospectively cap-
tured in the 4 categories of SCC, BCC, melanoma and 
other skin cancers and allow the association of these skin 
- Prospective cohort study of transplant recipients in Switzerland within the STCS
- Between May 2008 and June 2013
Inclusion criteria:
- All male and female recipients of solid organs in Switzerland registered in the STCS database with given informed consent
Exclusion criteria:
- Patients who withdraw their informed consent
- Recipients of non-solid organs
- Skin cancer data were collected from the STCS database
- Cases of skin cancer were validated with the patients‘ health history and pathology reports
- First and subsequent skin cancers were counted
- Skin cancers were classified into the following groups: SCC, BCC, melanoma, intra-epidermal cancers and others
- Intra-epidermal skin cancers were excluded from statistical calculation 
- Drug data (immunosuppressive drugs and antimicrobiological drugs) were collected from the STCS database with start and stop date
- Descriptive analysis was performed for patient‘s characteristics
- Skin cancer occurrence by types is presented by date and number of events
- Method of cumulative incidences was used to estimate the probability of skin cancer
- Risk factors for skin cancer were modelled using a traditional Cox proportional hazard model and an extended Cox proportional hazard 
   model
Fig. 1. Flowchart of Materials and Methods. STCS, Swiss Transplant Cohort Study; SCC, squamous cell carci-
noma; BCC, basal cell carcinoma.























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































cancer events with a large data pool on the individuals 
affected [14].
The present study aims to report the incidence of skin 
cancer overall and by cancer type within the STCS in the 
years 2008–2013. We present descriptive statistics for 
these skin cancers and report associated risk factors based 
on the high granularity of data captured in the STCS. 
Materials and Methods
For further details, see the online supplementary material (see 
www.karger.com/doi/10.1159/000510685) (Fig. 1) [14, 16–18].
Results
Between May 2008 and June 2013, 2,192 patients with 
solid organ transplantation were included in our report. 
The median follow-up time was 32.4 months. Most of the 
patients (56.7%) were kidney transplant recipients, fol-
lowed by liver, lung, heart, combined (i.e., kidney and 
pancreas) and other (i.e., pancreas, small bowel) trans-
plant recipients. The median age at transplantation was 
53.3 years, while 64.1% of the OTR were male. During 
follow-up 98% of the patients received glucocorticoids at 
least once, 10.3% azathioprine (AZA), 95.8% mycophe-
nolate mofetil, 98.6% a calcineurin inhibitor and 14.9% a 
mammalian target of rapamycin (mTOR) inhibitor. 317 
(14.5%) OTR were put on quinolones and 20 (0.9%) on 
voriconazole during our follow-up time. Full details are 
provided in Table 1.
As shown in Table 2 in detail, a total of 136 patients 
developed 335 cases of skin cancer during follow-up. 79 
patients developed SCC, 77 BCC, 6 melanoma and 5 oth-
er skin malignancies (dermal sarcoma, sarcoma not oth-
erwise specified, sebaceous gland carcinoma, Kaposi sar-
coma, atypically lymphocytic proliferation T-cell type). 
The cumulative incidence reached 6.2% for any skin can-
cer, 3.6% for SCC and 3.5% for BCC. 79.4% of the OTR 
with skin malignancy were male. 186 of these 335 skin 
cancer cases were SCC, 137 BCC, 7 melanoma and 5 oth-
er skin malignancies. This results in an SCC-to-BCC ratio 
of 1.4: 1. The median time to first skin cancer after trans-
plantation was 14 months (Table 3).
Figure 2 shows the probability of incident skin cancer 
during follow-up. With time after transplantation, the 
probability of SCC and BCC increases while the number 
of patients at risk decreases over time. Figure 3 shows the 
distribution of skin cancer after transplantation itemized 
for each skin cancer type. Each OTR with skin cancer is 
represented by a horizontal line. In Figure 4a–c skin can-
Table 2. Skin cancer cumulative incidence
Transplanted organ
kidney liver lung heart combined other all organs
Any skin cancer 92 (7.4) 15 (3.4) 14 (6.4) 6 (3.7) 3 (3.2) 6 (18.2) 136 (6.2)
Male 76 (82.6) 11 (73.3) 9 (64.3) 5 (83.3) 2 (66.7) 5 (83.3) 108 (79.4)
SCC 52 (4.2) 9 (2.0) 12 (5.5) 2 (1.2) 1 (1.1) 3 (9.1) 79 (3.6)
Male 42 (80.8) 8 (88.9) 8 (66.7) 1 (50.0) 1 (100.0) 2 (66.7) 62 (78.5)
BCC 56 (4.5) 9 (2.0) 2 (0.9) 5 (3.0) 2 (2.2) 3 (9.1) 77 (3.5)
Male 49 (87.5) 7 (77.8) 1 (50.0) 5 (100.0) 1 (50.0) 3 (100.0) 66 (85.7)
Melanoma 3 (0.2) 1 (0.2) 2 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 6 (0.3)
Male 3 (100.0) 1 (100.0) 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (100.0)
Other 1 (0.1) 2 (0.5) 2 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 5 (0.2)
Male 1 (100.0) 1 (50.0) 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (80.0)
Median time to first skin cancer 
(IQR), months 13.9 (8.4–22.7) 14.2 (8.9–22) 15.6 (6.5–19.5) 15.2 (12.5–22.5) 11.9 (7.4–17.3) 18.2 (3.9–36.8) 14 (8.4–22.7)
Skin cancer cases were divided into 4 groups: squamous cell carcinoma (SCC), basal cell carcinoma (BCC), melanoma and other. Other includes dermal 
sarcoma, sarcoma not otherwise specified, sebaceous gland carcinoma, Kaposi sarcoma and atypical lymphocytic proliferation of T-cell type. The number 
and percentage of all skin cancers and the different groups of skin cancer were calculated, as well as the number and percentage of male patients with skin 
cancer. Combined organ transplantations were transplantations of more than one organ at the same time and included 57 kidney and pancreas, 20 kidney 
and liver, 8 kidney and islet cells, 4 kidney and heart, 2 pancreas and small bowel transplantations, 1 liver and lung and 1 kidney, liver and islet cell 
transplantation. 21 double kidney transplantations were counted as kidney transplantation. Other transplanted organs included 1 small bowel, 9 pancreas 
and 23 islet cells transplantations. IQR, interquartile range.




cer cases per patient, classified into any skin cancer, SCC 
and BCC, are illustrated. The majority of patients suffered 
1 or 2 skin cancer cases, but there is a noticeable minority 
with a large number of tumours, especially SCC.
Multivariate analysis showed age at transplantation, 
male sex, skin cancer before inclusion into the STCS, pre-
vious transplantation and number of immunosuppres-
sive drugs as risk factors for the development of a first 
Table 3. Skin cancer events
Transplanted organ
kidney liver lung heart combined other all organs
Total number of skin cancer events, n (%) 233 (69.5) 46 (13.7) 32 (9.6) 7 (2.1) 4 (1.2) 13 (3.9) 335 (100.0)
Male, n (%) 211 (90.6) 42 (91.3) 27 (84.4) 6 (85.7) 3 (75.0) 12 (92.3) 301 (89.9)
Total number of SCC events, n (%) 128 (68.8) 23 (12.3) 21 (11.3) 2 (1.1) 2 (1.1) 10 (5.4) 186 (100.0)
Male, n (%) 116 (90.6) 22 (95.7) 17 (81.0) 1 (50.0) 2 (100.0) 9 (90.0) 167 (89.8)
Total number of BCC events, n (%) 101 (73.7) 19 (13.9) 7 (5.1) 5 (3.6) 2 (1.5) 3 (2.2) 137 (100.0)
Male, n (%) 91 (90.1) 17 (89.5) 6 (85.7) 5 (100.0) 1 (50.0) 3 (100.0) 123 (89.8)
Total number of melanoma events, n (%) 3 (42.8) 2 (28.6) 2 (28.6) 0 (0.0) 0 (0.0) 0 (0.0) 7 (100.0)
Male, n (%) 3 (100.0) 2 (100.0) 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 7 (100.0)
Total number of other events, n (%) 1 (20.0) 2 (40.0) 2 (40.0) 0 (0.0) 0 (0.0) 0 (0.0) 5 (100.0)
Male, n (%) 1 (100.0) 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (80.0)
Total number of skin cancer events during follow-up by transplanted organ and different skin cancer types. n, number; SCC, 
squamous cell carcinoma; BCC, basal cell number.
Table 4. Risk factors for first skin cancer overall
Risk factor Reference HR (95% CI) p value
Age at transplantation – 1.059 (1.04–1.079) <0.001
Male sex female sex 2.105 (1.36–3.259) 0.001
Previous skin cancer no previous skin cancer 5.3 (3.446–8.152) <0.001
Previous transplantation no previous transplantation 2.211 (1.505–3.248) <0.001
Number of immunosuppressive drugs – 1.332 (1.022–1.736) 0.034
The risk factors for first skin cancer were calculated using multivariate analysis. –, lack of reference; HR, hazard ratio; 95% CI, 95% 
confidence interval; see also Figure 3, legend text.
Table 5. Risk factors for recurrent skin cancer
Risk factor Reference HR (95% CI) p value
Age at transplantation (<2 years of transplant) – 1.036 (1.008–1.064) 0.01
Age at transplantation (>2 years of transplant) – 1.061 (1.029–1.094) <0.001
Male sex female sex 3.535 (2.234–5.595) <0.001
Previous skin cancer (<2 years of transplant) no previous skin cancer 9.413 (5.589–15.854) <0.001
Previous skin cancer (>2 years of transplant) no previous skin cancer 3.993 (1.565–10.189) 0.004
Previous transplantation (<2 years of transplant) no previous transplantation 2.576 (1.657–4.003) <0.001
Previous transplantation (>2 years of transplant) no previous transplantation 1.634 (0.732–3.648) 0.231
Number of immunosuppressive drugs – 1.160 (0.782–1.72) 0.46
The risk factors for recurrent skin cancer were calculated using multivariate analysis. –, lack of reference; HR, hazard ratio; 95% CI, 
95% confidence interval. 
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skin cancer overall (Table 4). For recurrent skin cancer, 
risk factors were age at transplantation, male sex, skin 
cancer before transplantation and also previous trans-
plantation during the first 2 years after transplantation 
(Table 5). The number of immunosuppressive drugs was 
not significant for the development of recurrent skin 
cancer overall, neither in recurrent SCC nor BCC (Tables 
6, 7).
Discussion and Conclusion
Our study reports the skin cancer incidence after 
transplantation of solid organs within the STCS. Our 
demographic results are comparable with previous 
studies. The median age in our study was slightly high-
er than in other studies, where age ranged between 41 
and 53 years at transplantation [19–22]. As in our study, 
most OTR included in studies from the USA, Australia, 
Sweden, Norway and Denmark were male [8, 19–24]. 
The majority of our patients received a kidney trans-
plant, followed by liver transplantation. Compared 
with our data, most studies showed a higher proportion 
of kidney transplant recipients around 76% [19–21]. 
Only one study from the USA showed a lower propor-
tion of kidney transplant recipients of 48% [22]. Me-
dian follow-up and number of our enrolled patients 
were less than in similar studies, which included 5,279–
10,649 patients with a median follow-up from 4 to 8 
years [19–22]. With an enrolment rate of 95% of trans-
plant recipients in Switzerland, our study population 
largely resembles the ones reported in other countries 
and is highly representative of the transplant popula-
tion in Switzerland [15]. 
Garrett et al. [22] showed an incidence rate of 8% for 
posttransplantation skin cancer in the USA. Australian 
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Fig. 2. Probability of incident skin cancer. 
Probability of incident skin cancer is dis-
played for squamous cell carcinoma (SCC), 
basal cell carcinoma (BCC), melanoma and 
other cancers over time and over number 
of patients at risk. “Other” includes dermal 
sarcoma, sarcoma not otherwise specified, 
sebaceous gland carcinoma, Kaposi sarco-
ma and atypical lymphocytic proliferation 
of T-cell type.
Fig. 3. Skin cancer events per patient after transplantation. Cases 
of skin cancer are displayed for squamous cell carcinoma (SCC) by 
open circles, basal cell carcinoma (BCC) by open squares, mela-
noma by open rhomboids and other cancers by open triangles over 
time. Grey bars represent the follow-up for each patient affected 
by skin cancer. “Other” includes dermal sarcoma, sarcoma not 
otherwise specified, sebaceous gland carcinoma, Kaposi sarcoma 
and atypical lymphocytic proliferation of T-cell type.
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Fig. 4. a Number of skin cancers per pa-
tient. OTR, organ transplant recipients. 
The y axis shows the number of patients in 
relation to the number of skin cancers on 
the x axis. b Number of squamous cell car-
cinoma (SCC) per patient. The y axis shows 
the number of patients in relation to the 
number of squamous cell carcinoma (SCC) 
on the x axis. c Number of basal cell carci-
noma (BCC) per patient. The y axis shows 
the number of patients in relation to the 
number of basal cell carcinoma (BCC) on 
the x axis. 
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dences of 7, 25 and 79% after 1, 5 and 20 years of follow-
up, respectively [8]. In Sweden the cumulative incidence 
of non-melanoma skin cancer (NMSC) after transplanta-
tion reached 6.7% after 10 years and 20.4% after 20 years 
of follow-up [25]. In an Italian registry-based study of 
kidney and heart transplant recipients, the cumulative in-
cidence reached 5.8 and 10.8% 5 and 10 years after trans-
plantation, respectively [26]. A Swiss long-term study of 
lung transplant recipients from 1992 till 2010 showed a 
cumulative incidence of SCC of 16.7 and 59.9% for 5 and 
15 years after transplantation, respectively [27]. Except 
for NMSC in Sweden and Italy, our cohort reports lower 
incidence rates. This might be due to the shorter follow-
up in our study, as skin cancer incidence in OTR seems 
to increase with duration of immunosuppression [8, 9, 
28–30]. Our data show an increasing probability of inci-
dent skin cancer with time after transplantation, in par-
ticular for SCC (Fig. 2).
Compared to our tumour data, several publications – 
including only heart and/or renal transplant recipients – 
showed a much higher SCC-to-BCC ratio ranging be-
tween 2 and 7: 1 [6, 7, 28, 31–34]. Studies including all 
solid transplant recipients from Israel and Denmark re-
ported an SCC-to-BCC ratio of 1.9: 1 [6] and 1: 1, respec-
tively [20], more in line with our data. Also studies from 
countries in southern Europe described lower SCC-to-
BCC ratios of 1.1: 1 in kidney transplant recipients in Por-
tugal [35], 1.1: 1 in Italian heart and 2.6: 1 in Italian kidney 
transplant recipients [26]. For the general population in 
Switzerland, only the Canton of Vaud reports numbers 
which show the SCC-to-BCC ratio at 1: 2.5 in the period 
between 1976 and 1992 [3]. The ratio of SCC to BCC in 
our present study might result from a rather short follow-
up where the impact of previous sun damage before trans-
plantation is still relatively predominant, while we expect 
an increase in the SCC-to-BCC ratio with a longer follow-
Table 6. Risk factors for recurrent SCC
Risk factor Reference HR (95% CI) p value
Age at transplantation (<2 years of transplant) – 1.019 (0.985–1.054) 0.272
Age at transplantation (>2 years of transplant) – 1.070 (1.035–1.106) <0.001
Male sex female sex 3.395 (1.912–6.028) <0.001
Previous skin cancer (<2 years of transplant) no previous skin cancer 14.523 (7.034–29.985) <0.001
Previous skin cancer (>2 years of transplant) no previous skin cancer 3.466 (1.521–7.899) 0.003
Previous transplantation (<2 years of transplant) no previous transplantation 3.747 (2.08–6.751) <0.001
Previous transplantation (>2 years of transplant) no previous transplantation 2.027 (0.962–4.271) 0.063
Number of immunosuppressive drugs – 1.174 (0.684–2.012) 0.561
The risk factors for recurrent squamous cell carcinoma (SCC) were calculated using multivariate analysis. –, lack of reference; HR, 
hazard ratio; 95% CI, 95% confidence interval.
Table 7. Risk factors for recurrent BCC
Risk factor Reference HR (95% CI) p value
Age at transplantation (<2 years of transplant) – 1.060 (1.028–1.093) <0.001
Age at transplantation (>2 years of transplant) – 1.059 (1.014–1.106) 0.01
Male sex female sex 3.605 (1.831–7.098) <0.001
Previous skin cancer (<2 years of transplant) no previous skin cancer 5.315 (3.22–8.776) <0.001
Previous skin cancer (>2 years of transplant) no previous skin cancer 5.009 (1.356–18.506) 0.016
Previous transplantation (<2 years of transplant) no previous transplantation 1.437 (0.895–2.308) 0.133
Previous transplantation (>2 years of transplant) no previous transplantation 1.399 (0.42–4.66) 0.584
Number of immunosuppressive drugs – 1.148 (0.726–1.813) 0.555
The risk factors for recurrent basal cell carcinoma (BCC) were calculated using multivariate analysis. –, lack of reference; HR, hazard 
ratio; 95% CI, 95% confidence interval.




up. Since AZA is known to increase especially the risk for 
SCC [36], another explanation for the lower SCC-to-BCC 
ratio in our study might be the low percentage of patients 
in our cohort receiving AZA compared to other similar 
cohorts, where the majority of the patient had AZA as 
component of their maintenance immunosuppressive 
therapy [7, 31–33].
Previous data showed that risk factors for NMSC after 
transplantation are age at transplantation, male sex, his-
tory of pretransplantation skin cancer, type of transplant-
ed organ, high sun exposure and fair skin type [8–10, 19, 
22, 26–28, 33, 37, 38]. Our study finds correspondingly 
age at transplantation, male sex, previous skin cancer and 
additionally previous transplantation as risk factors for 
first and recurrent skin cancer. The duration of immuno-
suppression correlates with the increased skin cancer risk 
after transplantation, while the type of immunosuppres-
sive drug seems an important risk factor [7, 8, 10, 31, 33, 
39]. Dantal et al. [40] demonstrated in 1998 that more 
kidney transplant recipients developed a malignant dis-
order on a normal-dose cyclosporine regimen compared 
to patients on a low-dose cyclosporine regimen. There 
were also more patients with multiple skin lesions in the 
normal-dose cyclosporine group [40]. A change in im-
munosuppressive regimen from calcineurin inhibitor to 
mTOR inhibitor induced fewer NMSC [41, 42]. AZA in-
creases UVA photosensitivity and subsequent photo-
damage, potentially leading to a higher skin cancer occur-
rence [43, 44]. Like many other studies we could not find 
an association for individual drugs with skin cancer. We 
did, however, find that the number of any immunosup-
pressive drugs is associated with the risk for a first skin 
cancer after transplantation, but not for recurrent skin 
cancer after transplantation. Our limited follow-up is the 
most likely limiting factor in associating skin cancer risk 
with individual immunosuppressants, followed by the 
limitation of our cohort data to the dose prescribed, not 
the trough levels achieved in serum. Selection bias for 
prescribing an mTOR inhibitor in high-risk individuals 
might also contribute. We hope that with a longer follow-
up time, our cohort study will yield data on the impact of 
individual immunosuppressants.
OTR with previous skin cancer showed a higher haz-
ard ratio for skin cancer in the first 2 years after transplan-
tation compared to the period beyond 2 years. We believe 
that these findings show the decreasing impact of pre-
existent conditions in the course after transplantation. 
Previous skin cancer as a static risk factor tends to lose 
impact over time. Immunosuppression as dynamically 
increasing risk factor, however, gains impact over time, 
both in time after transplantation and by accumulated 
immunosuppressant use. 
Limitations of our study are the limited number of skin 
cancer cases and the limited follow-up time of 36 months 
compared to similar studies. There is no matched control 
population because NMSC is not captured in the nation-
al cancer registry in Switzerland. Skin type and sun expo-
sure, as well as serum levels of immunosuppressive drugs, 
were not captured in the STCS, precluding analysis of 
these factors for risk association. 
Conclusion
In summary, our study is highly representative of the 
Swiss transplant recipient population. Skin cancer in-
creases following transplantation with an important im-
pact on morbidity and is associated with risk factors in 
our national cohort. Further follow-up will allow more 
granular dissection, for example, of individual immuno-
suppressants and their impact on skin cancer formation, 
potentially allowing immunosuppressive treatment re-
gimes tailored to individual skin cancer risks in our trans-
plant recipients.
Key Message
The incidence of skin cancer after organ transplantation is in-
creased. We found some important risk factors.
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